GR20020100513A - ΧΡΗΣΗ ΑΓΩΝΙΣΤΩΝ ΚΑΙ ΑΝΤΑΓΩΝΙΣΤΩΝ ΤΟΥ ΣΥΣΤΗΜΑΤΟΣ CRH - Ucm ΣΤΗ ΘΕΡΑΠΕΙΑ ΦΛΕΓΜΟΝΩΔΩΝ ΝΟΣΩΝ : ΑΜΕΣΕΣ ΡΥΘΜΙΣΤΙΚΕΣ ΔΡΑΣΕΙΣ ΤΟΥ ΣΥΣΤΗΜΑΤΟΣ CRH - Usm ΣΤΗ ΦΛΕΓΜΟΝΗ ΜΕΣΩ ΕΠΙΔΡΑΣΗΣ ΣΤΑ ΜΑΚΡΟΦΑΓΑ - Google Patents
ΧΡΗΣΗ ΑΓΩΝΙΣΤΩΝ ΚΑΙ ΑΝΤΑΓΩΝΙΣΤΩΝ ΤΟΥ ΣΥΣΤΗΜΑΤΟΣ CRH - Ucm ΣΤΗ ΘΕΡΑΠΕΙΑ ΦΛΕΓΜΟΝΩΔΩΝ ΝΟΣΩΝ : ΑΜΕΣΕΣ ΡΥΘΜΙΣΤΙΚΕΣ ΔΡΑΣΕΙΣ ΤΟΥ ΣΥΣΤΗΜΑΤΟΣ CRH - Usm ΣΤΗ ΦΛΕΓΜΟΝΗ ΜΕΣΩ ΕΠΙΔΡΑΣΗΣ ΣΤΑ ΜΑΚΡΟΦΑΓΑInfo
- Publication number
- GR20020100513A GR20020100513A GR20020100513A GR20020100513A GR20020100513A GR 20020100513 A GR20020100513 A GR 20020100513A GR 20020100513 A GR20020100513 A GR 20020100513A GR 20020100513 A GR20020100513 A GR 20020100513A GR 20020100513 A GR20020100513 A GR 20020100513A
- Authority
- GR
- Greece
- Prior art keywords
- crh
- monocyte
- inflammatory
- receptor
- macrophage
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 102100021752 Corticoliberin Human genes 0.000 abstract 7
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 abstract 7
- 210000002540 macrophage Anatomy 0.000 abstract 3
- 210000001616 monocyte Anatomy 0.000 abstract 3
- 108091005470 CRHR2 Proteins 0.000 abstract 2
- 102100038019 Corticotropin-releasing factor receptor 2 Human genes 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 108010063738 Interleukins Proteins 0.000 abstract 2
- 102000015696 Interleukins Human genes 0.000 abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 2
- 102100029793 Urocortin Human genes 0.000 abstract 2
- 108010059705 Urocortins Proteins 0.000 abstract 2
- 102000023732 binding proteins Human genes 0.000 abstract 2
- 108091008324 binding proteins Proteins 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 2
- 239000000777 urocortin Substances 0.000 abstract 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 abstract 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 abstract 1
- 102100038018 Corticotropin-releasing factor receptor 1 Human genes 0.000 abstract 1
- 101710198652 Corticotropin-releasing factor receptor 1 Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000020411 cell activation Effects 0.000 abstract 1
- 229940041967 corticotropin-releasing hormone Drugs 0.000 abstract 1
- 230000016396 cytokine production Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000028709 inflammatory response Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000000770 proinflammatory effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 208000037816 tissue injury Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Peptides Or Proteins (AREA)
Abstract
παρούσα ευρεσιτεχνία σχετίζεται με τη χρήση των ανταγωνιστών του υπότυπου CRH-R1 του κυτταρικού υποδοχέα της Εκλυτικής Ορμόνης της Κορτικοτροπίνης (corticotropine-releasing hormone, CRH) καθώς και/ή των αγωνιστών του υπότυπου CRH-R2του ανωτέρω υποδοχέα στη θεραπεία των φλεγμονωδών νόσων μέσω της ρύθμισης της ενεργοποίησης, πολλαπλασιασμού, διαφοροποίησης, ή/και απόπτωσης των μονοκύτταρων/μακροφάγων. Με τον όρο σύστημα του CRH προσδιορίζουμε τις φυσικές και συνθετικές ουσίες, αγωνιστές και ανταγωνιστές των CRH και Urocortin (Ucn) για τους κυτταρικούς υποδοχείς CRH-R1 και CRH-R2 και των υπότυπων τους καθώς και τη δεσμευτική πρωτείνη της CRH (CRH-building protein, BP), ένα ψευδο-υποδοχέα της CRH. Η ευρεσιτεχνία εστιάζει στις φαρμακολογικέςπαρεμβάσεις για τη βελτιστοποίηση της θεραπείας φλεγμονωδών νόσων με τη χρήση του συστήματος της CRH στον έλεγχο των μονοκύτταρων μακροφάγων τα οποία παίζουν καθοριστικό ρόλο στην έναρξη και διατήρηση της φλεγμονής μέσω της παραγωγής προ-γλεγμονωδώνκυτταροκινών, όπως π.χ. οι Ιντερλευκίνη 1 (IL)-1, η IL-6 και ο παράγων νέκρωσης των όγκων (tumor necrosis factor (TNF)-alpha). Με τον όρο φλεγμονή προσδιορίζουμε την απάντηση του οργανισμού σε επιβλαβείς ενδογενείς και εξωγενείς διεγέρσεις που προκαλούν ιστική βλάβη. Η φλεγμονή είναι μία αμυντική αντίδραση του ξενιστή που μπορεί όμως να καταλήξει και στη βλάβη του αμυνόμενου οργανισμού. Η ευρεσιτεχνία παρέχει επίσης μεθόδους για την in vitro και in vivo εκτίμηση των φυσικών και συνθετικών τροποποιητών του συστήματος της CRH ως παραγόντων ελέγχου των μονοκύτταρων/ μακροφάγων.
ΰ
Priority Applications (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20020100513A GR1004664B (en) | 2002-11-26 | 2002-11-26 | The charakteristics and advantages of our invention are illustrated by the following description, methods and results of our research, attached figures and supporting references |
| CA002506607A CA2506607A1 (en) | 2002-11-26 | 2003-11-26 | Use of the corticoliberin-urocortin system in the treatment of inflammatory diseases |
| KR1020057009538A KR20050085167A (ko) | 2002-11-26 | 2003-11-26 | Ｃｒｈ(코르티코트로핀 방출 호르몬)-ｕｃｎ(유로코르틴)시스템의 염증성 질병 치료에의 용도 |
| BR0316638-4A BR0316638A (pt) | 2002-11-26 | 2003-11-26 | Uso do sistema de crh (hormÈnio de liberação de corticotropina) ucn (urocortina) no tratamento de doenças inflamatórias |
| MXPA05005617A MXPA05005617A (es) | 2002-11-26 | 2003-11-26 | Uso del sistema hlc (hormona de liberacion de corticotropina -ucn (urocortin) en el tratamiento de enfermedades inflamatorias. |
| PL378271A PL378271A1 (pl) | 2002-11-26 | 2003-11-26 | Zastosowanie układu CRH (hormon uwalniający kortykotropinę) - UCN (urokortyna) w leczeniu chorób zapalnych |
| HR20050484A HRP20050484A2 (en) | 2002-11-26 | 2003-11-26 | Use of the corticoliberin-urocortin system in the treatment of inflammatory diseases |
| EP03811845A EP1565215A2 (en) | 2002-11-26 | 2003-11-26 | Use of the corticoliberin-urocortin system in the treatment of inflammatory diseases |
| NZ540455A NZ540455A (en) | 2002-11-26 | 2003-11-26 | Use of the CRH (corticotropin releasing hormone) - UCN (urocortin) system in the treatment of specific inflammatory disease |
| AU2003302368A AU2003302368B2 (en) | 2002-11-26 | 2003-11-26 | Use of the corticoliberin-urocortin system in the treatment of inflammatory diseases |
| CNA2003801042270A CN1756566A (zh) | 2002-11-26 | 2003-11-26 | 促肾上腺皮质素释放激素－尾加压素系统在治疗炎性疾病中的用途 |
| PCT/IB2003/005429 WO2004047866A2 (en) | 2002-11-26 | 2003-11-26 | Use of the corticoliberin-urocortin system in the treatment of inflammatory diseases |
| US10/535,307 US20060135417A1 (en) | 2002-11-26 | 2003-11-26 | Use of the crh (corticotropin releasing hormone)-ucn (urocortin) system in the treatment of inflammatory diseases |
| JP2004554845A JP2006509756A (ja) | 2002-11-26 | 2003-11-26 | 炎症性疾患の治療におけるｃｒｈ（副腎皮質刺激ホルモン放出ホルモン）−ｕｃｎ（ウロコルチン）系の使用 |
| IS7868A IS7868A (is) | 2002-11-26 | 2005-05-26 | Notkun á kortkólíberín-úrókortín kerfi í meðferð á bólguvaldandi sjúkdómum. |
| US12/409,300 US20090247558A1 (en) | 2002-11-26 | 2009-03-23 | Use of the crh (corticotropin releasing hormone) - ucn (urocortin) system in the treatment of inflammatory diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20020100513A GR1004664B (en) | 2002-11-26 | 2002-11-26 | The charakteristics and advantages of our invention are illustrated by the following description, methods and results of our research, attached figures and supporting references |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GR20020100513A true GR20020100513A (el) | 2004-07-19 |
| GR1004664B GR1004664B (en) | 2004-09-02 |
Family
ID=36441288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR20020100513A GR1004664B (en) | 2002-11-26 | 2002-11-26 | The charakteristics and advantages of our invention are illustrated by the following description, methods and results of our research, attached figures and supporting references |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20060135417A1 (el) |
| EP (1) | EP1565215A2 (el) |
| JP (1) | JP2006509756A (el) |
| KR (1) | KR20050085167A (el) |
| CN (1) | CN1756566A (el) |
| AU (1) | AU2003302368B2 (el) |
| BR (1) | BR0316638A (el) |
| CA (1) | CA2506607A1 (el) |
| GR (1) | GR1004664B (el) |
| HR (1) | HRP20050484A2 (el) |
| IS (1) | IS7868A (el) |
| MX (1) | MXPA05005617A (el) |
| NZ (1) | NZ540455A (el) |
| PL (1) | PL378271A1 (el) |
| WO (1) | WO2004047866A2 (el) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100204113A1 (en) * | 2007-09-11 | 2010-08-12 | Dorian Bevec | Use of stresscopin-related peptide as a therapeutic agent |
| EP2341915B1 (en) * | 2008-08-01 | 2019-03-20 | Centre National De La Recherche Scientifique | Phosphorylated dendrimers as antiinflammatory drugs |
| GB201210686D0 (en) | 2012-06-15 | 2012-08-01 | Holsboermaschmeyer Neurochemie Gmbh | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level |
| GB201310782D0 (en) | 2013-06-17 | 2013-07-31 | Max Planck Innovation Gmbh | Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms |
| JOP20170153A1 (ar) | 2016-07-15 | 2019-01-30 | Lilly Co Eli | نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة |
| US10729693B2 (en) * | 2018-03-02 | 2020-08-04 | Ponce Medical School Foundation, Inc. | Compositions and methods for the treatment of endometriosis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE177101T1 (de) * | 1992-12-17 | 1999-03-15 | Pfizer | Pyrrolopyrimidine als crf antagonisten |
| US20020082409A1 (en) * | 2000-10-26 | 2002-06-27 | Hsu Sheau Yu | Stresscopins and their uses |
-
2002
- 2002-11-26 GR GR20020100513A patent/GR1004664B/el not_active IP Right Cessation
-
2003
- 2003-11-26 EP EP03811845A patent/EP1565215A2/en not_active Withdrawn
- 2003-11-26 NZ NZ540455A patent/NZ540455A/en unknown
- 2003-11-26 HR HR20050484A patent/HRP20050484A2/hr not_active Application Discontinuation
- 2003-11-26 JP JP2004554845A patent/JP2006509756A/ja not_active Withdrawn
- 2003-11-26 WO PCT/IB2003/005429 patent/WO2004047866A2/en not_active Ceased
- 2003-11-26 MX MXPA05005617A patent/MXPA05005617A/es not_active Application Discontinuation
- 2003-11-26 AU AU2003302368A patent/AU2003302368B2/en not_active Ceased
- 2003-11-26 PL PL378271A patent/PL378271A1/pl not_active Application Discontinuation
- 2003-11-26 BR BR0316638-4A patent/BR0316638A/pt not_active IP Right Cessation
- 2003-11-26 KR KR1020057009538A patent/KR20050085167A/ko not_active Ceased
- 2003-11-26 CN CNA2003801042270A patent/CN1756566A/zh active Pending
- 2003-11-26 CA CA002506607A patent/CA2506607A1/en not_active Abandoned
- 2003-11-26 US US10/535,307 patent/US20060135417A1/en not_active Abandoned
-
2005
- 2005-05-26 IS IS7868A patent/IS7868A/is unknown
-
2009
- 2009-03-23 US US12/409,300 patent/US20090247558A1/en not_active Abandoned
Non-Patent Citations (4)
| Title |
|---|
| D. AGNELLO ET AL.: "Corticosteroid-independent inhibition of tumor necrosis factor production by the neuropeptide urocortin.", AMERICAN JOURNAL OF PHYSIOLOGY (ENDOCRINOLOGY AND METABOLISM), vol. 275, no. 5 part 1, November 1998 (1998-11-01), pages E757 - E762, XP002247896 * |
| E. DERMITZAKI ET AL.: "Corticotropin-releasing hormone induces Fas ligand production and apoptosis in PC12 cells via activation of p38 mitogen-activated protein kinase.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 14, 5 April 2002 (2002-04-05), BALTIMORE, MD, US, pages 12280 - 12287, XP002247898 * |
| S. AGELAKI ET AL.: "Corticotropin-releasing hormone augments proinflammatory cytokine production from macrophages in vitro and in lipopolysaccharide-induced endotoxin shock in mice.", INFECTION AND IMMUNITY, vol. 70, no. 11, November 2002 (2002-11-01), WASHINGTON, US, pages 6068 - 6074, XP002247895 * |
| Y. MURAMATSU ET AL.: "urocortin and corticotropin-releasing factor receptor expression in the human colonic mucosa.", PEPTIDES, vol. 21, no. 12, December 2000 (2000-12-01), pages 1799 - 1809, XP002247897 * |
Also Published As
| Publication number | Publication date |
|---|---|
| NZ540455A (en) | 2007-05-31 |
| BR0316638A (pt) | 2005-10-11 |
| IS7868A (is) | 2005-05-26 |
| AU2003302368A1 (en) | 2004-06-18 |
| HRP20050484A2 (en) | 2005-12-31 |
| WO2004047866A3 (en) | 2004-07-29 |
| PL378271A1 (pl) | 2006-03-20 |
| KR20050085167A (ko) | 2005-08-29 |
| US20060135417A1 (en) | 2006-06-22 |
| GR1004664B (en) | 2004-09-02 |
| US20090247558A1 (en) | 2009-10-01 |
| EP1565215A2 (en) | 2005-08-24 |
| CA2506607A1 (en) | 2004-06-10 |
| AU2003302368B2 (en) | 2007-10-11 |
| CN1756566A (zh) | 2006-04-05 |
| MXPA05005617A (es) | 2005-11-23 |
| WO2004047866A2 (en) | 2004-06-10 |
| JP2006509756A (ja) | 2006-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Marçais et al. | Regulation of mouse NK cell development and function by cytokines | |
| Robinson et al. | Cytokines. 3. Cytokines in asthma | |
| Pretolani | Interleukin-10: an anti-inflammatory cytokine with therapeutic potential. | |
| Banks et al. | Interleukin 12: a new clinical player in cytokine therapy | |
| Wang et al. | IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. | |
| Boyman et al. | The role of interleukin-2 during homeostasis and activation of the immune system | |
| Borish et al. | Update on cytokines | |
| Lipsky et al. | The role of cytokines in the pathogenesis of rheumatoid arthritis | |
| Kondo | The roles of keratinocyte-derived cytokines in the epidermis and their possible responses to UVA-irradiation | |
| Eaves et al. | Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 alpha, an inhibitor of primitive normal hematopoietic cells. | |
| Fukushi et al. | The activity of soluble VCAM-1 in angiogenesis stimulated by IL-4 and IL-13 | |
| O'Suilleabhain et al. | Interleukin-12 treatment restores normal resistance to bacterial challenge after burn injury | |
| Chen et al. | The molecular mechanisms supporting the homeostasis and activation of dendritic epidermal T cell and its role in promoting wound healing | |
| GR20020100513A (el) | ΧΡΗΣΗ ΑΓΩΝΙΣΤΩΝ ΚΑΙ ΑΝΤΑΓΩΝΙΣΤΩΝ ΤΟΥ ΣΥΣΤΗΜΑΤΟΣ CRH - Ucm ΣΤΗ ΘΕΡΑΠΕΙΑ ΦΛΕΓΜΟΝΩΔΩΝ ΝΟΣΩΝ : ΑΜΕΣΕΣ ΡΥΘΜΙΣΤΙΚΕΣ ΔΡΑΣΕΙΣ ΤΟΥ ΣΥΣΤΗΜΑΤΟΣ CRH - Usm ΣΤΗ ΦΛΕΓΜΟΝΗ ΜΕΣΩ ΕΠΙΔΡΑΣΗΣ ΣΤΑ ΜΑΚΡΟΦΑΓΑ | |
| Luger et al. | The role of cytokines and neuroendocrine hormones in cutaneous immunity and inflammation. | |
| Liew et al. | Role of interleukin 18 in rheumatoid arthritis | |
| Fietta et al. | Interleukins (ILS), a Fascinating Family of Cytokines: Part II: ILS from IL-20 to IL-38 | |
| Alam et al. | Cytokines in allergic inflammation | |
| Zhu et al. | Interleukin-13 inhibits cytokines synthesis by blocking nuclear factor-κB and c-Jun N-terminal kinase in human mesangial cells | |
| Moller et al. | Mast cells and their mediators in immediate and delayed immune reactions | |
| Mckenzie et al. | Effect of ultraviolet-inducible cytokines on melanoma growth in vivo: stimulation of melanoma growth by interleukin-1 and-6 | |
| Berczi et al. | Cytokines and chemokines | |
| Kam et al. | Cytokines and chemokines in inflammatory bowel disease | |
| Mingala et al. | Molecular cloning, sequencing and phylogenetic analysis of inflammatory cytokines of swamp type buffalo contrasting with other bubaline breeds | |
| Lévêque et al. | Regulation of interleukin 3 receptor α chain (IL-3Rα) on human monocytes by interleukin (IL)-4, IL-10, IL-13, and transforming growth factor β (TGF-β) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PG | Patent granted | ||
| ML | Lapse due to non-payment of fees |
Effective date: 20110602 |